~~<i id='ECCE562022'><strike id='ECCE562022'><tt id='ECCE562022'><pre id='ECCE562022'></pre></tt></strike></i>~~

Home» leisure time» Wikipedia

Wikipedia

author：explore 2025-09-29 02:42:19 Page View：65156

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Meta's Zuckerberg and Chan on track to put $50 billion into science
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

comprehensive

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Testing for cancer recurrence creates a new limbo for patients

EssayauthorMaraBuchbinderandherhusband,Jesse(right).CourtesyMaraBuchbinderMyhusband’scancercamebackt

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Paying for Covid pills will soon shift to insurers

PayingforCovidpills,includingPaxlovid,willshifttoinsurersstartingnextweek.JoeRaedle/GettyImagesWASHI